Top

Journal of Cancer Research and Clinical Oncology

Published in:

05-09-2023 | Hepatocellular Carcinoma | Research

Aberrant expression of cuproptosis‑related gene LIPT1 is associated with metabolic dysregulation of fatty acid and prognosis in hepatocellular carcinoma

Authors: Jinping Li, Dayun Tuo, Gunan Guo, Jinfeng Gan

Published in: Journal of Cancer Research and Clinical Oncology | Issue 17/2023

Abstract

Purpose

Lipoyltransferase 1 (LIPT1) has been recently identified as a cuproptosis‑related gene. As a key enzyme of lipoic acid metabolism, LIPT1 has been revealed to play important roles in hereditary diseases involved with lipoic acid biosynthesis defects, while its roles in hepatocellular carcinoma (HCC) remain to be elucidated. Hence, we aimed to explore the roles and mechanisms of LIPT1 in HCC progression.

Methods

The expression of LIPT1 in HCC tissues and its clinical significance for HCC were evaluated by bioinformatic analysis and in our patient cohort. The influences of LIPT1 on the growth, migration, and lipid metabolism of HCC cells were assessed in vitro. The underlying mechanisms were explored using gene set enrichment analysis (GSEA) and molecular experiments.

Results

LIPT1 expression was significantly elevated in HCC tissues compared to the normal tissues, and such upregulation was associated with more malignant pathological features and poor prognosis of patients with HCC. LIPT1 silencing significantly inhibited cell proliferation, migration, and lipid content. GSEA revealed that LIPT1 upregulation was significantly associated with various cancer-associated signaling pathways, including the PI3K-AKT signaling pathway and the Wnt/β-catenin pathway. Further molecular experiments indicated that LIPT1 silencing repressed the expression of peroxisome proliferator-activated receptor gamma (PPARγ) and inactivated the AKT/GSK-3β/β-catenin signaling axis.

Conclusions

Upregulation of LIPT1 is involved in metabolic dysregulation of fatty acid and poor prognosis of HCC patients, which suggests that LIPT1 plays an important role in reprogramming lipid metabolism and could act as a potential prognostic marker and therapeutic target for HCC.

Available only for authorised users

Bacci M, Lorito N, Smiriglia A, Morandi A (2021) Fat and furious: lipid metabolism in antitumoral therapy response and resistance. Trends Cancer 7:198–213. https://doi.org/10.1016/j.trecan.2020.10.004CrossRefPubMed

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC et al (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39:782–795. https://doi.org/10.1016/j.immuni.2013.10.003CrossRefPubMed

Cheng C, Geng F, Cheng X, Guo D (2018) Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun (lond) 38:27. https://doi.org/10.1186/s40880-018-0301-4CrossRefPubMed

Clough E, Barrett T (2016) The gene expression omnibus database. Methods Mol Biol 1418:93–110. https://doi.org/10.1007/978-1-4939-3578-9_5CrossRefPubMedPubMedCentral

Fagerberg L, Hallström BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J et al (2014) Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteom 13:397–406. https://doi.org/10.1074/mcp.M113.035600CrossRef

Fujiwara K, Suzuki M, Okumachi Y, Okamura-Ikeda K, Fujiwara T, Takahashi E et al (1999) Molecular cloning, structural characterization and chromosomal localization of human lipoyltransferase gene. Eur J Biochem 260:761–767. https://doi.org/10.1046/j.1432-1327.1999.00204.xCrossRefPubMed

Galbraith LCA, Mui E, Nixon C, Hedley A, Strachan D, MacKay G et al (2021) PPAR-gamma induced AKT3 expression increases levels of mitochondrial biogenesis driving prostate cancer. Oncogene 40:2355–2366. https://doi.org/10.1038/s41388-021-01707-7CrossRefPubMedPubMedCentral

Grinchuk OV, Yenamandra SP, Iyer R, Singh M, Lee HK, Lim KH et al (2018) Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma. Mol Oncol 12:89–113. https://doi.org/10.1002/1878-0261CrossRefPubMed

Hänzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform 14:7. https://doi.org/10.1186/1471-2105-14-7CrossRef

Krishnamurthy N, Kurzrock R (2018) Targeting the Wnt/beta-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treat Rev 62:50–60. https://doi.org/10.1016/j.ctrv.2017.11.002CrossRefPubMed

Li J, Huang Q, Long X, Zhang J, Huang X, Aa J et al (2015) CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARα pathways. J Hepatol 63:1378–1389. https://doi.org/10.1016/j.jhep.2015.07.039CrossRefPubMed

Lim HY, Sohn I, Deng S, Lee J, Jung SH, Mao M et al (2013) Prediction of disease-free survival in hepatocellular carcinoma by gene expression profiling. Ann Surg Oncol 20:3747–3753. https://doi.org/10.1245/s10434-013-3070-yCrossRefPubMed

Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD et al (2018) Integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173:400–416. https://doi.org/10.1016/j.cell.2018.02.052CrossRefPubMedPubMedCentral

Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. https://doi.org/10.1186/s13059-014-0550-8CrossRefPubMedPubMedCentral

Lv H, Liu X, Zeng X, Liu Y, Zhang C, Zhang Q et al (2022) Comprehensive analysis of cuproptosis-related genes in immune infiltration and prognosis in melanoma. Front Pharmacol 13:930041. https://doi.org/10.3389/fphar.2022.930041CrossRefPubMedPubMedCentral

Martinez-Reyes I, Chandel NS (2021) Cancer metabolism: looking forward. Nat Rev Cancer 21:669–680. https://doi.org/10.1038/s41568-021-00378-6CrossRefPubMed

Mayr JA, Feichtinger RG, Tort F, Ribes A, Sperl W (2014) Lipoic acid biosynthesis defects. J Inherit Metab Dis 37:553–563. https://doi.org/10.1007/s10545-014-9705-8CrossRefPubMed

Mehraj U, Ganai RA, Macha MA, Hamid A, Zargar MA, Bhat AA et al (2021) The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities. Cell Oncol (dordr) 44:1209–1229. https://doi.org/10.1007/s13402-021-00634-9CrossRefPubMed

Mei S, Chen X, Wang K, Chen Y (2023) Tumor microenvironment in ovarian cancer peritoneal metastasis. Cancer Cell Int 23:11. https://doi.org/10.1186/s12935-023-02854-5CrossRefPubMedPubMedCentral

Moldogazieva NT, Zavadskiy SP, Sologova SS, Mokhosoev IM, Terentiev AA (2021) Predictive biomarkers for systemic therapy of hepatocellular carcinoma. Expert Rev Mol Diagn 21:1147–1164. https://doi.org/10.1080/14737159.2021.1987217CrossRefPubMed

Munir R, Lisec J, Swinnen JV, Zaidi N (2019) Lipid metabolism in cancer cells under metabolic stress. Br J Cancer 120:1090–1098. https://doi.org/10.1038/s41416-019-0451-4CrossRefPubMedPubMedCentral

Ni M, Solmonson A, Pan C, Yang C, Li D, Notzon A et al (2019) Functional assessment of lipoyltransferase-1 deficiency in cells, mice, and humans. Cell Rep 27:1376-1386.e6. https://doi.org/10.1016/j.celrep.2019.04.005CrossRefPubMedPubMedCentral

Patitucci C, Couchy G, Bagattin A, Cañeque T, de Reyniès A, Scoazec JY et al (2017) Hepatocyte nuclear factor 1α suppresses steatosis-associated liver cancer by inhibiting PPARγ transcription. J Clin Invest 127:1873–1888. https://doi.org/10.1172/JCI90327CrossRefPubMedPubMedCentral

Pavlova NN, Zhu J, Thompson CB (2022) The hallmarks of cancer metabolism: still emerging. Cell Metab 34:355–377. https://doi.org/10.1016/j.cmet.2022.01.007CrossRefPubMedPubMedCentral

Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M (2018) The immunology of hepatocellular carcinoma. Nat Immunol 19(3):222–232. https://doi.org/10.1038/s41590-018-0044-zCrossRefPubMed

Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS et al (2010) A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 70:10202–10212. https://doi.org/10.1158/0008-5472.CAN-10-2607CrossRefPubMedPubMedCentral

Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A et al (2023) Immune checkpoint therapy-current perspectives and future directions. Cell 186:1652–1669. https://doi.org/10.1016/j.cell.2023.03.006CrossRefPubMed

Snaebjornsson MT, Janaki-Raman S, Schulze A (2020) Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer. Cell Metab 31:62–76. https://doi.org/10.1016/j.cmet.2019.11.010CrossRefPubMed

Solmonson A, DeBerardinis RJ (2018) Lipoic acid metabolism and mitochondrial redox regulation. J Biol Chem 293:7522–7530. https://doi.org/10.1074/jbc.TM117.000259CrossRefPubMed

Song M, Bode AM, Dong Z, Lee MH (2019) AKT as a therapeutic target for cancer. Cancer Res 79:1019–1031. https://doi.org/10.1158/0008-5472.CAN-18-2738CrossRefPubMed

Soreze Y, Boutron A, Habarou F, Barnerias C, Nonnenmacher L, Delpech H et al (2013) Mutations in human lipoyltransferase gene LIPT1 cause a Leigh disease with secondary deficiency for pyruvate and alpha-ketoglutarate dehydrogenase. Orphanet J Rare Dis 8:192. https://doi.org/10.1186/1750-1172-8-192CrossRefPubMedPubMedCentral

Tommasini-Ghelfi S, Murnan K, Kouri FM, Mahajan AS, May JL, Stegh AH (2019) Cancer-associated mutation and beyond: the emerging biology of isocitrate dehydrogenases in human disease. Sci Adv 5(5):eaaw4543. https://doi.org/10.1126/sciadv.aaw4543CrossRefPubMedPubMedCentral

Tort F, Ferrer-Cortès X, Thió M, Navarro-Sastre A, Matalonga L, Quintana E et al (2014) Mutations in the lipoyltransferase LIPT1 gene cause a fatal disease associated with a specific lipoylation defect of the 2-ketoacid dehydrogenase complexes. Hum Mol Genet 23:1907–1915. https://doi.org/10.1093/hmg/ddt585CrossRefPubMed

Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M et al (2022) Copper induces cell death by targeting lipoylated TCA cycle proteins. Science 375:1254–1261. https://doi.org/10.1126/science.abf0529CrossRefPubMedPubMedCentral

Xue W, Dong B, Wang Y, Xie Y, Li P, Gong Z et al (2022) A novel prognostic index of stomach adenocarcinoma based on immunogenomic landscape analysis and immunotherapy options. Exp Mol Pathol 128:104832. https://doi.org/10.1016/j.yexmp.2022.104832CrossRefPubMed

Yan W, Wu X, Zhou W, Fong MY, Cao M, Liu J et al (2018) Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol 20:597–609. https://doi.org/10.1038/s41556-018-0083-6CrossRefPubMedPubMedCentral

Yan C, Niu Y, Ma L, Tian L, Ma J et al (2022) System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma. J Transl Med 20:452. https://doi.org/10.1186/s12967-022-03630-1CrossRefPubMedPubMedCentral

Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR (2019) A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16:589–604. https://doi.org/10.1038/s41575-019-0186-yCrossRefPubMedPubMedCentral

Yi M, Li A, Zhou L, Chu Q, Luo S, Wu K (2021) Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma. Cancer Immunol Immunother 70:1705–1719. https://doi.org/10.1007/s00262-020-02817-zCrossRefPubMedPubMedCentral

Yu G, Wang LG, Han Y, He QY et al (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16:284–287. https://doi.org/10.1089/omi.2011.0118CrossRefPubMedPubMedCentral

Zhang C, Guo C, Li Y, Liu K, Zhao Q, Ouyang L (2021) Identification of claudin-6 as a molecular biomarker in pan-cancer through multiple omics integrative analysis. Front Cell Dev Biol 9:726656. https://doi.org/10.3389/fcell.2021.726656CrossRefPubMedPubMedCentral

Zhu W, Peng Y, Wang L, Hong Y, Jiang X, Li Q et al (2018) Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy. Hepatology 68:574–589. https://doi.org/10.1002/hep.29844CrossRefPubMed

Zuo Q, He J, Zhang S, Wang H, Jin G, Jin H et al (2021) PPARγ coactivator-1α suppresses metastasis of hepatocellular carcinoma by inhibiting Warburg effect by PPARγ-dependent WNT/β-catenin/pyruvate dehydrogenase kinase isozyme 1 axis. Hepatology 73:644–660. https://doi.org/10.1002/hep.31280CrossRefPubMed

Title: Aberrant expression of cuproptosis‑related gene LIPT1 is associated with metabolic dysregulation of fatty acid and prognosis in hepatocellular carcinoma
Authors: Jinping Li
Dayun Tuo
Gunan Guo
Jinfeng Gan
Publication date: 05-09-2023
Publisher: Springer Berlin Heidelberg
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: Journal of Cancer Research and Clinical Oncology / Issue 17/2023
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-023-05325-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 17/2023

Development and validation of a disulfidptosis and M2 TAM-related classifier for bladder cancer to explore tumor subtypes, immune landscape and drug treatment

Frequency of social burden and underage children in neuro-oncological patients

Causal relationship between lung diseases and risk of esophageal cancer: insights from Mendelian randomization

Construction of the survival nomograms for colon cancer patients of different ages based on the SEER database

A practical recurrence risk model based on Lasso-Cox regression for gastric cancer

Development and external validation of the multichannel deep learning model based on unenhanced CT for differentiating fat-poor angiomyolipoma from renal cell carcinoma: a two-center retrospective study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials